OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Hitchins on the Association Between Constitutional MLH1 Methylation and MRD in Select Cancers

August 15th 2023

Megan Hitchins, PhD, discusses results from an analysis on the prevalence of high-risk constitutional MLH1 methylation in early-onset colorectal and endometrial cancers displaying mismatch repair deficiency.

Dr Spira on the Ongoing Investigation of MYTX-011 in NSCLC

August 15th 2023

Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.

Dr Chari on the FDA Approval of Talquetamab in Relapsed/Refractory Multiple Myeloma

August 14th 2023

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

Dr Alumkal on the Effects of the ARESENS Trial on the Treatment of mHSPC

August 14th 2023

Joshi Alumkal, MD, discusses the effects of the phase 3 ARESENS trial on the treatment of metastatic hormone-sensitive prostate cancer.

Dr Sonpavde on the Future of Treating Bladder Cancer

August 14th 2023

Guru P. Sonpavde, MD, discusses the future of bladder cancer treatment, including potential novel targets and further research with immunotherapy and antibody-drug conjugates.

Dr Qin on Choosing Between Targetable Agents in EGFR Exon 20–Mutated Lung Cancer

August 14th 2023

Angel Qin, MD, discusses her process when choosing between targetable agents for patients with EGFR exon 20–mutated lung cancer.

Dr Conlin on CDK4/6 Inhibitor Sequencing and QOL in Breast Cancer

August 11th 2023

Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.

Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC

August 11th 2023

Corey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.

Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLC

August 10th 2023

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast Cancer

August 10th 2023

Denise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.

Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer

August 10th 2023

Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.

Dr Barroilhet on the Role of PARP Inhibitors in BRCA+ and HRD Ovarian Cancer

August 10th 2023

Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.

Dr Hays on Unmet Needs in CRC

August 10th 2023

John L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.

Dr Halpern on the MANIFEST Trial of Pelabresib and Ruxolitinib in Myelofibrosis

August 10th 2023

Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCC

August 10th 2023

Shawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).

Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer

August 9th 2023

Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.

Dr Fonkoua on Alternatives to Platinum Chemotherapy in Cancer Care

August 9th 2023

Lionel A. Kankeu Fonkoua, MD, discusses challenges arising from the ongoing shortage of platinum chemotherapy in the United States and suggests potential alternatives to cisplatin that may benefit patients with cancer during this shortage.

Dr Manana on How Systemic Racism Appears in Oncology

August 9th 2023

Ana I. Velazquez Manana, MD, MSc, discusses how systemic racism appears in oncology.

Dr Cecchini on the Results of the PROSPECT Trial in Rectal Cancer

August 9th 2023

Michael Cecchini, MD, discusses the phase 3 PROSPECT trial of neoadjuvant chemoradiation vs neoadjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy with selective use of chemoradiation, followed by total mesorectal excision in patients with locally advanced rectal cancer, and how this regimen may fit into the current treatment landscape for rectal cancer.

Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast Cancer

August 9th 2023

Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.